Quarterly ResultAug 6, 2026, 04:15 PM
Agomab Reports H1 2026 Results; Cash Runway into H1 2029
AI Summary
Agomab Therapeutics reported its half-year 2026 financial results, showcasing a strong cash position of €252 million, including $208 million gross proceeds from its recent IPO, which is expected to fund operations into the first half of 2029. The company announced regulatory alignment with the FDA on the design of its NOV-ERA Phase 2b study for Ontunisertib in Fibrostenosing Crohn’s Disease. Agomab is on track to initiate this Phase 2b study and a Phase 2 study for AGMB-447 in Idiopathic Pulmonary Fibrosis in the second half of 2026, with key topline data from ongoing studies anticipated soon.
Key Highlights
- Cash and cash investments totaled €252.0 million as of June 30, 2026.
- Raised $208 million in gross proceeds from IPO, extending cash runway into H1 2029.
- Achieved FDA alignment on NOV-ERA Phase 2b study design for Ontunisertib in FSCD.
- Topline data from STENOVA OLE study and AGMB-447 Phase 1b IPF study expected in coming months.
- On track to initiate NOV-ERA Phase 2b (FSCD) and AGMB-447 Phase 2 (IPF) studies in H2 2026.
- Net loss was €31.0 million for H1 2026, compared to €26.9 million for H1 2025.
- R&D expenses were €23.0 million for H1 2026, up from €22.0 million in H1 2025.
- USPTO granted a patent covering the composition of matter of AGMB-447.
Price Impact
More from AGMB